B. Riley has initiated Foghorn Therapeutics (NASDAQ:FHTX) at buy citing the company's development of SMARCA2 inhibitors to fight tumors. The investment bank has a $10 price target (~151% upside ...

— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...